Chargement en cours...
Pan-transcriptome-based candidate therapeutic discovery for idiopathic pulmonary fibrosis
BACKGROUND: There are two US Food and Drug Administration (FDA)-approved drugs, pirfenidone and nintedanib, for treatment of patients with idiopathic pulmonary fibrosis (IPF). However, neither of these drugs provide a cure. In addition, both are associated with several drug-related adverse events. H...
Enregistré dans:
| Publié dans: | Ther Adv Respir Dis |
|---|---|
| Auteurs principaux: | , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
SAGE Publications
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7659024/ https://ncbi.nlm.nih.gov/pubmed/33167785 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1753466620971143 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|